Abstract
Background: The aim of our study was to evaluate the relationship between C-peptide and DPN in community-based patients with type 2 diabetes.
Methods: In total, 220 consecutive type 2 diabetic patients treated by our regional medical consortium were enrolled. DPN was assessed by clinical symptoms, signs, and electromyography.
Results: Fasting C-peptide, 2-h postprandial C-peptide and ΔC-peptide (i.e., 2-h postprandial C-peptide minus the fasting C-peptide) serum concentrations in the non-DPN group were significantly higher than those in the clinical DPN group (all P ≤ 0.040) and the confirmed DPN group (all P < 0.002). The three C-peptide parameters were independently associated with DPN (all P < 0.05) after adjusting for age, sex, diabetes duration, smoking status, systolic pressure, body mass index, angiotensin-converting enzyme inhibitors/ angiotensin receptor blocker use, fasting plasma glucose, HbA1c, triglyceride and estimated glomerular filtration rate. Compared with the ΔC-peptide quartile 1 (reference), patients in quartile 3 (odds ratio [OR], 0.110; 95% confidence interval [CI] 0.026–0.466; P = 0.003) and quartile 4 (OR, 0.012; 95% CI 0.026–0.559; P = 0.007) had a lower risk of DPN after adjusting for the confounders.
Conclusion: C-peptide was negatively associated with DPN in community-based type 2 diabetic patients.
Keywords: Diabetic peripheral neuropathy, C-peptide, Beta-cell function, Community-based.
References
1. Young MJ, Boulton AJ, MacLeod AF, et al. A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic popula-tion. Diabetologia. 1993;36:150–154.
2. Stockl K, Vanderplas A, Tafesse E, et al. Costs of lower-extremity ulcers among patients with diabetes. Diabetes Care. 2004;27:2129–2134.
3. Tesfaye S, Boulton AJ, Dyck PJ, et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care. 2010;33:2285–2293.
4. Palmer JP, Fleming GA, Greenbaum CJ, et al. C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21–22 October 2001. Diabetes. 2004;53:250–264.
5. Yosten GL, Kolar GR. The physiology of proinsulin C-Peptide: unanswered questi-ons and a proposed model. Physiology (Bethesda). 2015;30:327–332.
6. Johansson J, Ekberg K, Shafqat J, et al. Molecular effects of proinsulin C-peptide. Biochem Biophys Res Commun. 2002;295:1035–1040.
7. Panero F, Novelli G, Zucco C, et al. Fasting plasma C-peptide and micro- and macrovascular complications in a large clinic-based cohort of type 1 diabetic patients. Diabetes Care. 2009;32:301–305.
8. Johansson BL, Borg K, Fernqvist-Forbes E, et al. Beneficial effects of C-peptide on incipient nephropathy and neuropathy in patients with Type 1 diabetes mellitus. Diabetic Med. 2000;17:181–189.
9. Ekberg K, Brismar T, Johansson BL, et al. C-Peptide replacement therapy and sensory nerve function in type 1 diabetic neuropathy. Diabetes Care. 2007;30:71–76
10. Yosten GL, Maric-Bilkan C, Luppi P, et al. Physiological effects and therapeutic potential of proinsulin C-peptide. Am J Physiol Endocrinol Metab. 2014;307: E955–E968.
11. Kim BY, Jung CH, Mok JO, et al. Association between serum C-peptide levels and chronic microvascular complications in Korean type 2 diabetic patients. Acta Diabetol. 2012;49:9–15.
12. Bo S, Gentile L, Castiglione A, et al. C-peptide and the risk for incident complications and mortality in type 2 diabetic patients: a retrospective cohort study after a 14-year follow-up. Eur J Endocrinol. 2012;167:173–180.
13. Zhao L, Ma J, Wang S, et al. Relationship between beta-cell function, metabolic control, and microvascular complications in type 2 diabetes mellitus. Diabetes Technol Ther. 2015;17:29–34.
14. Sari R, Balci MK. Relationship between C peptide and chronic complications in type-2 diabetes mellitus. J Natl Med Assoc. 2005;97:1113–1118.
15. Gottsater A, Ahmed M, Fernlund P, et al. Autonomic neuropathy in Type 2 diabetic patients is associated with hyperins-ulinaemia and hypertriglycerida-emia. Diabetic Med. 1999;16:49–54.
16. World Health Organization . Diabetes mellitus: report of a WHO study group. Geneva: World Health Organ-ization; 2006.
17. Han L, Ji L, Chang J, et al. Peripheral neuropathy is associated with insulin resistance independent of metabolic syndr-ome. Diabetol Metab Syndr. 2015;7:14.
18. Ma YC, Zuo L, Chen JH, et al. Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J Am Soc Nephrol: JASN. 2006;17:2937–2944.
19. Xiaofu T. Clinical EMG study. The Beijing University of Science and Technology China harmony Medical College unites the publishing house. Beijing; 1995.
20. Rigler R, Pramanik A, Jonasson P, et al. Specific binding of proinsulin C-peptide to human cell membranes. Proc Natl Acad Sci USA. 1999;96:13318–13323.
21. Zhang W, Yorek M, Pierson CR, et al. Human C-peptide dose dependently prevents early neuropathy in the BB/Wor-rat. Int J Exp Diabetes Res. 2001;2:187–193.
22. Wahren J, Larsson C. C-peptide: new find-ings and therapeutic possibilities. Diabetes Res Clin Pract. 2015;107: 309–319.
23. Pierson CR, Zhang W, Sima AA. Proinsulin C-peptide replacement in type 1 diabetic BB/Wor-rats prevents deficits in nerve fiber regeneration. J Neuropathol Exp Neurol. 2003;62:765–779.
24. Sima AA, Zhang W, Li ZG, et al. Molecular alterations underlie nodal and paranodal degeneration in type 1 diabetic neuropathy and are prevented by C-peptide. Diabetes. 2004;53:1556–1563.
25. Kamiya H, Zhang W, Sima AA. The beneficial effects of C-Peptide on diabetic polyneuropathy. Rev Diabet Stud. 2009; 6:187–202.
DOI: https://dx.doi.org/10.18535/jmscr/v5i4.41
